Rosetta Genomics tumbles as Aegis turns negative

Rosetta Genomics (ROSG -19.1%) slides hard on heavy volume.

The move appears to be attributable to Aegis, where analysts have downgraded the shares to Hold from Buy.

Price target is now $3.50 (from $10).

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs